Ingenol mebutate

Drug Profile

Ingenol mebutate

Alternative Names: 3-Ingenyl angelate; I3A; Ingenol-3-angelate; PEP-005; PEP005-015; Picato

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer LEO Pharma; Peplin
  • Class Antineoplastics; Ingenols; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Warts
  • No development reported Basal cell cancer; Bladder cancer; Leukaemia; Squamous cell cancer

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Actinic keratosis(Combination therapy) in USA (Topical, Gel)
  • 30 Mar 2017 LEO Pharma completes a phase I trial in Warts in USA (Topical) (NCT02748902)
  • 01 Mar 2017 LEO Pharma completes a phase III trial for Actinic keratosis in USA (NCT02361216)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top